Nov 26, 2021
The articles are called “The new synthesis: How synthetic DNA technology is changing drug discovery” and “In vitro drug interaction data critical in drug repurposing”. The first was written by Dr Tim Brears, CEO of Evonetix and Dr Raquel Sanches-Kuiper, Director of Biology at Evonetix. The second was written by Madison Knapp, Marketing Communications Specialist, and Dr. Brian Ogilvie, Vice President of Scientific Consulting, at SEKISUI XenoTech.
In “The new synthesis: How synthetic DNA technology is changing drug discovery”, Dr Tim Brears and Dr Raquel Sanches-Kuiper explore applications of synthetic DNA in drug discovery and development, the benefits and limitations of current methods, and the opportunities offered by emerging DNA synthesis technologies.
In the wake of Covid-19 interest in repurposing a drug for a different indication to the one it was developed for has been high. In “In vitro drug interaction data critical in drug repurposing”, Madison Knapp and Dr. Brian Ogilvie offer insight into the process.